Once weekly fluconazole for antifungal prophylaxis post-liver transplantation

HPB

Volumn 15, Issue 7, 2013, Pages 541-547

  Trudeau, Raelene E ^a   Bowman, Lyndsey J ^a   Wills, Angela R ^a   Crippin, Jeffrey S ^b   Chapman, William C ^b   Anderson, Christopher ^b  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; COTRIMOXAZOLE; FLUCONAZOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; ANTIFUNGAL AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CANDIDA ALBICANS; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT SURVIVAL; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; LENGTH OF STAY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; RETROSPECTIVE STUDY; SYSTEMIC MYCOSIS; THRUSH; YOUNG ADULT; DRUG ADMINISTRATION; INCIDENCE; MICROBIOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MYCOSIS; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; UNITED STATES; EPIDEMIOLOGY; MYCOSES;

ADULT; ANTIFUNGAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUCONAZOLE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INTENSIVE CARE UNITS; LENGTH OF STAY; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; MISSOURI; MULTIVARIATE ANALYSIS; MYCOSES; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892642478     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12006     Document Type: Article

References (15)

1. Rabkin JM, Oroloff SL, Corless CL, Benner KG, Flora KD, Rosen HR et al. (2000) Association of fungal infection and increased mortality in liver transplant recipients. Am J Surg 179:426-430.
2. Hadley S, Samore MH, Lewis WD, Jenkins RL, Karchmer AW, Hammer SM. (1995) Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 59:851-859.
3. Collins LA, Samore MH, Roberts MS, Luzzati R, Jenkins RL, Lewis WD et al. (1994) Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 170:644-652.
4. Playford EG, Webster AC, Sorrell TC, Craig JC. (2006) Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 25:549-561.
5. Singh N, Wagener MM, Cacciarelli TV, Levitsky J. (2008) Antifungal management practices in liver transplant recipients. Am J Transplant 8:426-431.
6. Pappas PG, Andes D, Schuster M, Hadley S, Rabkin J, Merion RM et al. (2006) Invasive fungal infections in low-risk liver transplant recipients : a multi-center prospective observational study. Am J Transplant 6:386- 391.
7. Reed A, Herndon JB, Ersoz N, Fujikawa T, Schain D, Lipori P et al. (2007) Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients. Liver Transpl 13:1743-1750.
8. Karchmer AW, Samore MH, Hadley S, Collins LA, Jenkins RL, Lewis WD. (1995) Fungal infections complicating orthotopic liver transplantation. Trans Am Clin Climatol Assoc 106:38-47.
9. George MJ, Snydman DR, Werner BG, Griffith J, Falagas ME, Dougherty NN et al. (1997) The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Am J Med 103:106-113.
10. Patel R, Portela D, Badley AD, Harmsen WS, Larson-Keller JJ, Ilstrup DM et al. (1996) Risk factors of invasive candida and non-candida fungal infections after liver transplantation. Transplantation 62:926-934.
11. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE et al. (2009) Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503-535.
12. Briegel J, Forst H, Spill B, Haas A, Grabein B, Haller M et al. (1995) Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 14:375-382.
13. Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. (2006) Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 12:850-858.
14. Menzin J, Meyers J, Friedman M, Korn J, Perfect J, Langston A et al. (2011) The economic costs to United States hospitals of invasive fungal infections in transplant patients. Am J Infect Control 39:e15-e20.
15. Hadley S, Huckabee C, Pappas PG, Daly J, Rabkin J, Kauffman CA et al. (2009) Outcomes of antifungal prophylaxis in high-risk liver transplant recipients. Transpl Infect Dis 11:40-48.